A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based…
Big investment push: Sun Pharma Labs to set up Rs 3000 crore facility in MP We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
India’s largest drug maker Sun Pharmaceutical Industries has launched its global innovative drug Ilumya (tildrakizumab) in the country, the company said in an announcement on Monday. Ilumya is used in the treatment of plaque psoriasis. “Ilumya offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,” said…
Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA (Tildrakizumab) has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis….
Indian generic drugmakers are recalibrating their pricing strategy after Danish drugmaker Novo Nordisk decided to cut by nearly 40% prices of its weight-loss injectable semaglutide, sold under brand name Wegovy. Companies preparing for the first wave of semaglutide launches are now said to be working with a ₹3,000-5,000 band as against a ₹7,000-8,000 a month…
Sun Pharma Gets CDSCO Panel Nod to Conduct Active Post-Marketing Study for Antacid Combination Tablet We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Sun Pharma Wins Rs 828 Crore Excise Refund Battle, CESTAT Rules Revenue Demand Legally Unsustainable We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
NPPA Fixes Retail Prices for 28 Drug Formulations Including Dapagliflozin, Telmisartan, Amoxycillin, Details We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
For the first time ever, India’s largest drug maker, Sun Pharmaceutical, saw its US sales of innovative medicines overtake its generics sales in the second quarter of the financial year. The growth was primarily led by the sale of Ilumya, used for the treatment of psoriasis; the ophthalmic product Cequa; and the skin cancer drug…
For the first time ever, India’s largest drug maker Sun Pharmaceutical saw its US sales of innovative medicines overtaking generics sales in the second quarter of the financial year. The growth was primarily led by the sale of Ilumya, used for treatment of psoriasis; ophthalmic product Cequa and skin cancer drug Odomzo, a top company…